M
Michael A. Pulsipher
Researcher at Children's Hospital Los Angeles
Publications - 396
Citations - 17362
Michael A. Pulsipher is an academic researcher from Children's Hospital Los Angeles. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 55, co-authored 348 publications receiving 13335 citations. Previous affiliations of Michael A. Pulsipher include Huntsman Cancer Institute & University of Washington.
Papers
More filters
Journal ArticleDOI
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
Shannon L. Maude,Theodore W. Laetsch,Jochen Buechner,S. Rives,Michael Boyer,Henrique Bittencourt,Peter Bader,Michael R. Verneris,Heather E. Stefanski,G.D. Myers,Muna Qayed,B. De Moerloose,Hidefumi Hiramatsu,Krysta Schlis,Kara L. Davis,Paul L. Martin,Eneida R. Nemecek,Gregory A. Yanik,Christina Peters,André Baruchel,Nicolas Boissel,Francoise Mechinaud,Adriana Balduzzi,Joerg Krueger,Carl H. June,Bruce L. Levine,Patricia A. Wood,Tanya Taran,Mimi Leung,Karen Thudium Mueller,Yiyun Zhang,Kapildeb Sen,David Lebwohl,Michael A. Pulsipher,Stephan A. Grupp +34 more
TL;DR: In this global study of CAR T‐cell therapy, a single infusion of tisagenlecleucel provided durable remission with long‐term persistence in pediatric and young adult patients with relapsed or refractory B‐cell ALL, with transient high‐grade toxic effects.
Journal ArticleDOI
Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors
Claudio Anasetti,Brent R. Logan,Stephanie J. Lee,Edmund K. Waller,Daniel J. Weisdorf,John R. Wingard,Corey Cutler,Peter Westervelt,Ann E. Woolfrey,Stephen Couban,Gerhard Ehninger,Laura Johnston,Richard T. Maziarz,Michael A. Pulsipher,David L. Porter,Shin Mineishi,John M. McCarty,Shakila P. Khan,Paolo Anderlini,William I. Bensinger,Susan F. Leitman,Scott D. Rowley,Christopher Bredeson,Shelly L. Carter,Mary M. Horowitz,Dennis L. Confer +25 more
TL;DR: A phase 3, multicenter, randomized trial of transplantation of peripheral-blood stem cells versus bone marrow from unrelated donors did not detect significant survival differences, and exploratory analyses of secondary end points indicated that peripheral- Blood stem cells may reduce the risk of graft failure, whereas bone marrow may reduceThe risk of chronic GVHD.
Journal ArticleDOI
Transplantation Outcomes for Severe Combined Immunodeficiency, 2000–2009
Sung-Yun Pai,Brent R. Logan,Linda M. Griffith,Rebecca H. Buckley,Roberta E. Parrott,Christopher C. Dvorak,Neena Kapoor,Imelda C. Hanson,Alexandra H. Filipovich,Soma Jyonouchi,Kathleen E. Sullivan,Trudy N. Small,Lauri Burroughs,Suzanne Skoda-Smith,Ann E. Haight,Audrey Grizzle,Michael A. Pulsipher,Ka Wah Chan,Ramsay Fuleihan,Elie Haddad,Brett Loechelt,Victor M. Aquino,Alfred P. Gillio,Jeffrey H. Davis,Alan P. Knutsen,Angela R. Smith,Theodore B. Moore,Marlis L. Schroeder,Frederick D. Goldman,James A. Connelly,Matthew H. Porteus,Qun Xiang,William T. Shearer,Thomas A. Fleisher,Donald B. Kohn,Jennifer M. Puck,Luigi D. Notarangelo,Morton J. Cowan,Richard J. O'Reilly +38 more
TL;DR: Transplants from donors other than matched siblings were associated with excellent survival among infants with SCID identified before the onset of infection.
Journal ArticleDOI
HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies.
Michael B. Maris,Dietger Niederwieser,Brenda M. Sandmaier,Barry E. Storer,Monic J. Stuart,David G. Maloney,Effie W. Petersdorf,Peter A. McSweeney,Michael A. Pulsipher,Ann E. Woolfrey,Thomas R. Chauncey,Ed Agura,Shelly Heimfeld,John T. Slattery,Ute Hegenbart,Claudio Anasetti,Karl G. Blume,Rainer Storb +17 more
TL;DR: HLA-matched unrelated donor HCT after nonmyeloablative conditioning is feasible in patients ineligible for conventional HCT, and G-PBMCs conferred higher donor T-cell chimerism, greater durable engraftment, and better progression-free and overall survivals compared with marrow.
Journal ArticleDOI
Comorbidity-Age Index: A Clinical Measure of Biologic Age Before Allogeneic Hematopoietic Cell Transplantation
Mohamed L. Sorror,Rainer Storb,Brenda M. Sandmaier,Richard T. Maziarz,Michael A. Pulsipher,Michael B. Maris,Smita Bhatia,Fabiana Ostronoff,H. Joachim Deeg,Karen L. Syrjala,Elihu H. Estey,David G. Maloney,Frederick R. Appelbaum,Paul J. Martin,Barry E. Storer +14 more
TL;DR: The proposed composite measure allows integration of both comorbidities and age into clinical decision making and comparative-effectiveness research of HCT and shows age is a poor prognostic factor.